» Articles » PMID: 12085179

Tissue Levels of Active Matrix Metalloproteinase-2 and -9 in Colorectal Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 2002 Jun 27
PMID 12085179
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The bioactivity of matrix metalloproteinases was studied in tissues from colorectal cancer patients by means of both quantitative gelatin zymography and a fluorometric activity assay. Next to paired samples of tumour tissue and distant normal mucosa (n=73), transitional tissue was analysed from a limited (n=33) number of patients. Broad-spectrum matrix metalloproteinase activity and both the active and latent forms of the gelatinases matrix metalloproteinase-2 and -9 were higher in tumour than in normal mucosa. The ratio's between active and latent forms of matrix metalloproteinase-2 and -9 were highest in tumour tissue and normal mucosa, respectively. Matrix metalloproteinase-2 levels, both active and latent forms, correlated inversely with stage of disease, the tumours without synchronous distant metastases containing significantly (P=0.005) more active matrix metalloproteinase-2 than the others. At much lower levels of activity, the same trend was observed in distant normal mucosa. The level of latent form of matrix metalloproteinase-9 in tumour depended on tumour location. Neither the active form of matrix metalloproteinase-9 nor broad-spectrum matrix metalloproteinase activity in tumour tissue did correlate with any of the clinicopathological parameters investigated. The results demonstrate explicit differences between the activity of matrix metalloproteinase-2 and -9, indicating different roles for both gelatinases in tumour progression. Such data are necessary in order to develop rational anti-cancer therapies based on inhibition of specific matrix metalloproteinases.

Citing Articles

Detecting Colorectal Neoplasia Using Specific Fecal Fluorogenic Protease-Sensitive Substrates: A Pilot Study.

Opperman R, Bosch S, Nazmi K, Bikker F, Brand H, Jimenez C Anal Chem. 2024; 96(51):20239-20246.

PMID: 39665576 PMC: 11672227. DOI: 10.1021/acs.analchem.4c04586.


Association of gene polymorphisms with breast cancer risk: A narrative review.

Akter T, Aziz M, Islam M, Sarwar M Health Sci Rep. 2023; 6(10):e1607.

PMID: 37841939 PMC: 10570771. DOI: 10.1002/hsr2.1607.


The Curcuminoid EF24 in Combination with TRAIL Reduces Human Renal Cancer Cell Migration by Decreasing MMP-2/MMP-9 Activity through a Reduction in HO.

Ibanez Gaspar V, McMorrow T Int J Mol Sci. 2023; 24(2).

PMID: 36674555 PMC: 9863498. DOI: 10.3390/ijms24021043.


Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling.

Kwon Y, Park S, Nguyen B, Kim M, Oh S, Lee H Sci Rep. 2021; 11(1):17130.

PMID: 34429501 PMC: 8385024. DOI: 10.1038/s41598-021-96635-7.


Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.

Bade A, McMillan J, Liu Y, Edagwa B, Gendelman H Mol Neurobiol. 2021; 58(11):5703-5721.

PMID: 34390469 PMC: 8599359. DOI: 10.1007/s12035-021-02508-5.


References
1.
DeClerck Y . Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 2000; 36(10):1258-68. DOI: 10.1016/s0959-8049(00)00094-0. View

2.
Zeng Z, Guillem J . Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer. 1996; 74(8):1161-7. PMC: 2075925. DOI: 10.1038/bjc.1996.511. View

3.
Beekman B, Drijfhout J, Ronday H, TeKoppele J . Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. Ann N Y Acad Sci. 1999; 878:150-8. DOI: 10.1111/j.1749-6632.1999.tb07681.x. View

4.
Parsons S, Watson S, Collins H, Griffin N, Clarke P, Steele R . Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer. 1998; 78(11):1495-502. PMC: 2063205. DOI: 10.1038/bjc.1998.712. View

5.
McKerrow J, Bhargava V, Hansell E, Huling S, Kuwahara T, Matley M . A functional proteomics screen of proteases in colorectal carcinoma. Mol Med. 2000; 6(5):450-60. PMC: 1949953. View